Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study.
Diebold M, Vietzen H, Schatzl M, Mayer KA, Haindl S, Heinzel A, Hittmeyer P, Herz CT, Hopfer H, Menter T, Kühner LM, Berger SM, Puchhammer-Stöckl E, Doberer K, Steiger J, Schaub S, Böhmig GA. Diebold M, et al. Among authors: vietzen h. Transplantation. 2024 Oct 15. doi: 10.1097/TP.0000000000005228. Online ahead of print. Transplantation. 2024. PMID: 39402708
Immunomodulatory soluble HLA-G and HLA-E are associated with rapidly deteriorating CLAD and HCMV viremia after lung transplantation.
Kühner LM, Berger SM, Djinovic M, Furlano PL, Steininger LM, Pirker AL, Jaksch P, Puchhammer-Stöckl E, Vietzen H. Kühner LM, et al. Among authors: vietzen h. J Heart Lung Transplant. 2024 Dec;43(12):2036-2041. doi: 10.1016/j.healun.2024.07.014. Epub 2024 Jul 25. J Heart Lung Transplant. 2024. PMID: 39059595 Free article.
Natural Killer Cell Presence in Antibody-Mediated Rejection.
Diebold M, Farkash EA, Barnes J, Regele H, Kozakowski N, Schatzl M, Mayer KA, Haindl S, Vietzen H, Hidalgo LG, Halloran PF, Eskandary F, Böhmig GA. Diebold M, et al. Among authors: vietzen h. Transpl Int. 2024 Jun 24;37:13209. doi: 10.3389/ti.2024.13209. eCollection 2024. Transpl Int. 2024. PMID: 38979120 Free PMC article.
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F, Doberer K, Patel UD, Dudani JS, Regele H, Kozakowski N, Kläger J, Boxhammer R, Amann K, Puchhammer-Stöckl E, Vietzen H, Beck J, Schütz E, Akifova A, Firbas C, Gilbert HN, Osmanodja B, Halleck F, Jilma B, Budde K, Böhmig GA. Mayer KA, et al. Among authors: vietzen h. N Engl J Med. 2024 Jul 11;391(2):122-132. doi: 10.1056/NEJMoa2400763. Epub 2024 May 25. N Engl J Med. 2024. PMID: 38804514 Clinical Trial.
Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation.
Diebold M, Vietzen H, Heinzel A, Haindl S, Herz CT, Mayer K, Doberer K, Kainz A, Faé I, Wenda S, Kühner LM, Berger SM, Puchhammer-Stöckl E, Kozakowski N, Schaub S, Halloran PF, Böhmig GA. Diebold M, et al. Among authors: vietzen h. Am J Transplant. 2024 May;24(5):743-754. doi: 10.1016/j.ajt.2023.12.005. Epub 2023 Dec 13. Am J Transplant. 2024. PMID: 38097018 Free article.
28 results